On April 27, 2021, Jay Scollins notified Helix Acquisition Corp. of his decision to resign from his position as Chief Financial Officer, effective April 30, 2021. Mr. Scollins’ decision to resign is not related to any disagreement with the Company or its auditors on any matter relating to the Company’s operations, policies or practices. The board of directors of the Company has appointed Andrew Phillips as Chief Financial Officer, effective April 30, 2021. Dr. Phillips, 50, is a Managing Director at Cormorant Asset Management, LP, where he has served since 2020. Prior to joining Cormorant Asset Management, LP, Dr. Phillips served at C4 Therapeutics Inc., a company pioneering targeted protein degradation medicines, from 2016, most recently as the President and Chief Executive Officer from 2018 to 2020. Prior to joining C4 Therapeutics Inc., Dr. Phillips was Senior Director, Center for Development of Therapeutics at the Broad Institute of MIT and Harvard, where he led overall therapeutic efforts and provided strategic leadership for a number of major partnerships from 2014 to 2016.